Healthcare generative AI startup Hippocratic AI, which several health systems have invested in, is moving into life sciences with its acquisition of Grove AI.
Hippocratic AI has also named a president of life sciences, appointed a life sciences executive advisory council, and partnered with Boston Consulting Group on life sciences strategy.
The deal for Grove AI, which was unveiled Jan. 12, gives Hippocratic AI agentic AI capabilities for pharma research and development and clinical trial operations. Terms of the agreement were not disclosed.
Hippocratic AI, which reached “unicorn” status in 2025 with a $3.5 billion valuation, has had such health system investors as Cincinnati Children’s, Scottsdale, Ariz.-based HonorHealth, Columbus-based OhioHealth, King of Prussia, Pa.-based Universal Health Services and York, Pa.-based WellSpan Health.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
